Arthritis Foundation issues first CBD guidance

  • Arthritis Foundation

  • International Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • The Arthritis Foundation has issued guidance for affected consumers interested in using cannabidiol (CBD)-based products for arthritis symptoms (e.g., pain, insomnia, anxiety).

Why this matters

  • CBD is not a substitute for DMARD rheumatoid arthritis (RA) treatments.
  • Advise patients interested in trying CBD to choose standardized, quality-controlled products manufactured in the United States, backed by a certificate of analyses.
  • Aside from e-cigarettes and vaping lung injuries, no major safety issues have been found with the class of CBD products overall, when taken in moderate amounts.
  • Potential drug-drug interactions may occur: corticosteroids, tofacitinib, naproxen, celecoxib, tramadol, certain selective serotonin reuptake inhibitors, fibromyalgia medications.
  • Patients experiencing adverse effects should immediately discontinue use and contact their clinician.

Key points

  • Guidance was driven by a recent survey among ~3000 patients with osteoarthritis, RA, 79% of whom reported past or current CBD use or considering trying.
  • Caution patients using liquid CBD to learn both dosing and CBD amount in each dose.
  • Sublingual CBD: start with a few milligrams twice daily; increase by the same amount after several weeks if relief is inadequate or continue use as-is if inadequate.
  • Do not add tetrahydrocannabinol to CBD product without speaking to the clinician.